Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Merck & Co., Inc. (MRK) Presents at UBS BioPharma Conference (Transcript)
12:10pm, Saturday, 11'th Nov 2023
Merck & Co., Inc. (NYSE:MRK ) UBS BioPharma Conference November 8, 2023 12:00 PM ET Company Participants Jannie Oosthuizen - President, U.S. Human Health Business, Merck Conference Call Participants T
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
07:25am, Saturday, 11'th Nov 2023
Merck and Bristol Myers Squibb are developing antibody-drug conjugates. Both are acquiring biotechs and assets to beef up their pipelines.
Merck's drug Keytruda recommended for EU approval for biliary tract cancer
09:12am, Friday, 10'th Nov 2023
Merck & Co Inc (NYSE:MRK) announced Friday that its drug Keytruda has been backed by the European Medicines Agency's Committee for Medicinal Products in Human Use (CHMP) for use in certain patients wi
WHO's new COVID guidelines see fewer patients requiring hospitalization
08:43am, Friday, 10'th Nov 2023
Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.
7 Safe Stocks to Buy if You Think Q3's Gangbuster Growth Won't Last
09:26am, Thursday, 09'th Nov 2023
At first glance, the proposal to dive into safe stocks to buy might appear overly conservative. As NPR recently pointed out, the U.S. GDP grew 4.9% in the third quarter, catalyzed by stronger-than-exp
Grab these 2 funds with rich 11%-12% yields while you can
07:18am, Wednesday, 08'th Nov 2023
With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.
November Dogs Of The Dow: 3 Buyable, 4 Watchable
04:28pm, Monday, 06'th Nov 2023
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.�
3 Trustworthy Blue-Chip Stocks to Buy Now
09:00am, Saturday, 04'th Nov 2023
As economic uncertainty rises, blue-chip stocks to buy can provide stability for the prudent investor. Typically, these are resilient and established businesses with a track record of steady performan
Investor patience tested as pharmaceutical stocks take a tumble
06:07am, Wednesday, 01'st Nov 2023
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
10:15am, Tuesday, 31'st Oct 2023
Merck and Daiichi Sankyo just signed a multibillion-dollar drug collaboration. The pair will work to develop three medicines to eventually replace Keytruda.
5 Buy Rated Stocks For November 2023
09:30am, Saturday, 28'th Oct 2023
S&P 500 has fallen 10% since August 1st, providing opportunities to buy high-quality stocks at discounted prices. Volatility levels have creeped higher and could remain for the foreseeable future, whi
BMO Capital upgrades Merck to 'outperform'
01:52pm, Friday, 27'th Oct 2023
BMO has upgraded Merck to outperform from market perform.
Analyst: Merck Stock Could Jump 25%
10:15am, Friday, 27'th Oct 2023
BMO Capital upgraded shares of pharmaceutical company Merck & Co., Inc. (NYSE:MRK) to "outperform" from "market perform" and hiked its price target to $132.
Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV Shot
04:25pm, Thursday, 26'th Oct 2023
Merck (MRK) posted better-than-expected results on strong sales of its popular Keytruda cancer drug and HPV vaccine Gardasil, as well as a jump in demand for its Lagevrio COVID-19 treatment.
Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript
02:43pm, Thursday, 26'th Oct 2023
Merck & Co., Inc. (NYSE:MRK ) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Rob Davis - Chairman and CEO Carol
